. 2020 Jun 8;12(11):10663–10675. doi: 10.18632/aging.103285

Table 3. Impact of immune-related adverse events on response to PD-1 inhibitors therapy.

	Total (n=93)	Number of irAEs				irAEs grade
	Total (n=93)	Any (n=54)	None (n=39)	1-2 (n=31)	≥3 (n=23)	1-2 (n=46)	3-4 (n=8)
CR, n (%)	2(2.2)	2(3.7)	0(0.0)	0(0.0)	2(8.7)	2(4.3)	0(0.0)
PR, n (%)	19(20.4)	16(29.6)	3(7.7)	6(19.4)	10(43.5)	15(32.6)	1(12.5)
SD, n (%)	17(18.3)	11(20.4)	6(15.4)	5(16.1)	6(26.1)	8(17.4)	3(37.5)
PD, n (%)	55(59.1)	25(46.3)	30(76.9)	20(64.5)	5(21.7)	21(45.7)	4(50.0)
ORR, % (95% CI)	22.6 (14.0-32.3)	33.3 (20.4-46.3)	7.7 (0.0-17.9)	19.4 (6.5-35.5)	42.2 (30.4-69.6)	40.0 (23.9-50.0)	12.5 (0.0-37.5)
P₁		0.004^a		0.148^a	<0.001^a	0.002^a	0.657^a 0.176^c
DCR, % (95% CI)	40.9 (31.2-51.6)	53.7 (38.9-66.7)	23.1 (10.3-38.5)	35.5 (19.4-51.6)	78.3 (60.9-95.7)	54.3 (41.3-69.6)	50.0 (12.5-87.5)
P₂		0.003^a		0.254^a	<0.001^a <0.001^b	0.003^a	0.121^a 0.820^c

Abbreviations: irAEs, immune-related adverse events; CR, complete remission; PR, partial remission; SD, stable disease; PD, progressive disease; ORR, objective response rate; DCR, Disease control rate

^a Versus no immune-related adverse events.

^b Versus 1-2 immune-related adverse events.

^c Versus Grade 1-2 immune-related adverse events.